ARCHIVES

Afinitor Increases Overall Survival To 3.5 Years in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

RFA: Clinical Correlative Studies In Solid Tumors

April 3, 1992

NCI Drug Development Program Produced 7 Drugs In 10 Years, Chabner Tells Group

February 3, 1995

Gallo’s Deputy Removed Pending Investigation

January 11, 1991

NCI Gets Withheld Funds; Hazleton Tops List In Stepped-Up Award Flow

April 4, 1975

Ten-Year Breast Cancer Survival Improved In Past 60 Years, MD Anderson Study Finds

October 29, 2010

NCAB Settles PDQ Controversy; More CCOP Awards May Be Made, Center Guidelines Revisions Coming

October 7, 1983